Cancer Family
Head and Neck Neoplasm
CI-CAN-00000021Explore in graph →
Non-malignant1,571 active trials17 approved drugs142 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000021Explore in graph →
Clinical trials
6,372 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT02901483 | A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer | terminated | Phase 1 / Phase 2 | 12 | PharmaEngineINDUSTRY | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04052204 |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors |
| terminated |
| Phase 1 / Phase 2 |
| 3 |
| PfizerINDUSTRY |
| 4 |
| Oct 14, 2021 |
| clinicaltrials |
| NCT04252248 | Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After Radiotherapy or as Novel Late Salvage(DERANO) | terminated | Phase 1 | 3 | University Hospital HeidelbergOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT03131206 | A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | terminated | Phase 1 | 2 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 31, 2021 | clinicaltrials |
| NCT02817113 | Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer | terminated | Phase 1 | 4 | Orient Europharma Co., Ltd.INDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT03515824 | Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001) | terminated | Phase 1 | 22 | Merck Sharp & Dohme LLCINDUSTRY | 2 | Mar 9, 2021 | clinicaltrials |
| NCT02201355 | Hypofractionated Reduced-Volume Chemoradiation for T1/2N0-2 SCC Head and Neck | terminated | Phase 1 | 8 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT03818542 | A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 | 3 | AbbVieINDUSTRY | 1 | Dec 31, 2020 | clinicaltrials |
| NCT01602315 | A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 179 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 29, 2020 | clinicaltrials |
| NCT03246854 | A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer | terminated | Phase 1 | 6 | National Health Research Institutes, TaiwanOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT03655444 | Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy | terminated | Phase 1 / Phase 2 | 6 | Washington University School of MedicineOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | terminated | Phase 1 | 5 | Fore BiotherapeuticsINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 200 | AbbVieINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | terminated | Phase 1 | 16 | Seagen Inc.INDUSTRY | 1 | Sep 17, 2020 | clinicaltrials |
| NCT00603941 | A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel | terminated | Phase 1 / Phase 2 | 19 | Daiichi SankyoINDUSTRY | 1 | Sep 16, 2020 | clinicaltrials |
| NCT02464137 | HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer(HYDRA) | terminated | Phase 1 | 15 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | terminated | Phase 1 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 29, 2020 | clinicaltrials |
| NCT02842125 | Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer | terminated | Phase 1 / Phase 2 | 4 | MultiVir, Inc.INDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT01057277 | RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer | terminated | Phase 1 | 3 | howard safranOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02569788 | Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma | terminated | Phase 1 / Phase 2 | 9 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02801487 | Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma | terminated | Phase 1 / Phase 2 | 6 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | terminated | Phase 1 | 21 | Tocagen Inc.INDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT02429089 | Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck(CETLEE011) | terminated | Phase 1 | 21 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT02110992 | Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck | terminated | Phase 1 | 7 | University of CincinnatiOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT02124850 | A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab | terminated | Phase 1 | 18 | CelgeneINDUSTRY | 1 | Oct 25, 2019 | clinicaltrials |
| NCT02629549 | Intraoperative Imaging of Pituitary Adenomas by OTL | terminated | Phase 1 | 33 | University of PennsylvaniaOTHER | 1 | Aug 6, 2019 | clinicaltrials |
| NCT01739439 | Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery | terminated | Phase 1 | 6 | Fox Chase Cancer CenterOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT00832559 | A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients (VLA-X06)(VLA-X06) | terminated | Phase 1 | 4 | ViralyticsINDUSTRY | 1 | Jul 19, 2019 | clinicaltrials |
| NCT01987375 | Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures | terminated | Phase 1 | 1 | Eben RosenthalOTHER | 1 | Jun 24, 2019 | clinicaltrials |
| NCT00896350 | MRI in Finding Hypoxia in Patients Undergoing Chemo and Radiation for Head and Neck Cancer | terminated | Phase 1 | 10 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 18, 2019 | clinicaltrials |
| NCT01871311 | A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors | terminated | Phase 1 | 15 | Georgetown UniversityOTHER | 1 | Feb 8, 2019 | clinicaltrials |
| NCT02205398 | Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy | terminated | Phase 1 | 13 | Novartis PharmaceuticalsINDUSTRY | 7 | Jan 22, 2019 | clinicaltrials |
| NCT00882583 | A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC(Dasatinib) | terminated | Phase 1 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 9, 2019 | clinicaltrials |
| NCT00573989 | Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer | terminated | Phase 1 / Phase 2 | 27 | Wake Forest University Health SciencesOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT00923247 | A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) | terminated | Phase 1 / Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT01493154 | Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients | terminated | Phase 1 | 2 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 23, 2018 | clinicaltrials |
| NCT00102635 | 4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC) | terminated | Phase 1 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT02602067 | 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients(Tenatumomab) | terminated | Phase 1 | 2 | sigma-tau i.f.r. S.p.A.INDUSTRY | 2 | Sep 18, 2018 | clinicaltrials |
| NCT01732640 | A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC. | terminated | Phase 1 / Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 26, 2018 | clinicaltrials |
| NCT01009346 | RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN | terminated | Phase 1 / Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 17, 2018 | clinicaltrials |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | terminated | Phase 1 | 18 | Celldex TherapeuticsINDUSTRY | 1 | Apr 30, 2018 | clinicaltrials |
| NCT00901537 | Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer | terminated | Phase 1 | 8 | Loma Linda UniversityOTHER | 1 | Apr 17, 2018 | clinicaltrials |
| NCT00004261 | EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma | terminated | Phase 1 | — | University Health Network, TorontoOTHER | 1 | Feb 22, 2018 | clinicaltrials |
| NCT01012362 | Study of Pazopanib and Ixabepilone in Patients With Solid Tumors | terminated | Phase 1 | 31 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00570674 | Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck | terminated | Phase 1 / Phase 2 | 29 | Dana-Farber Cancer InstituteOTHER | 0 | Nov 13, 2017 | clinicaltrials |
| NCT02538627 | Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib | terminated | Phase 1 | 5 | Merrimack PharmaceuticalsINDUSTRY | 1 | Sep 5, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Feb 8, 2022source: clinicaltrials